Imunon Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
IMNN Nasdaq 8731 https://imunon.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Imunon Inc

IMNN: Results from OVATION 2 Study in Mid-2024… - May 16th, 2024 3:02 pm
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting - May 15th, 2024 12:30 pm
Q1 2024 Imunon Inc Earnings Call - May 14th, 2024 10:08 am
Imunon Inc (IMNN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ... - May 14th, 2024 7:02 am
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study - May 13th, 2024 1:00 pm
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update - May 13th, 2024 12:00 pm
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO - May 8th, 2024 12:00 pm
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024 - May 6th, 2024 3:00 pm
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101 - Apr 18th, 2024 12:30 pm
IMNN: IND Application Submitted for Phase 1/2 Trial of Seasonal COVID-19 Vaccine… - Apr 12th, 2024 10:41 am
IMUNON Reports Compliance with Nasdaq Listing Requirements - Apr 11th, 2024 12:00 pm
Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Call Transcript - Apr 1st, 2024 11:08 pm
IMUNON Reports 2023 Financial Results and Provides Business Update - Mar 28th, 2024 12:00 pm
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses - Mar 25th, 2024 12:30 pm
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024 - Mar 21st, 2024 9:00 pm
IMUNON Files IND Application to Begin Human Testing of IMNN-101 - Mar 13th, 2024 12:00 pm
IMUNON Announces Leadership Change - Mar 12th, 2024 9:00 pm
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5 - Feb 29th, 2024 1:30 pm
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer - Feb 27th, 2024 1:30 pm
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine - Feb 22nd, 2024 1:00 pm